Advertisement
Organisation › Details
Mogrify (Group)
Mogrify has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management. *
Start | 2016-02-12 established | |
Industry | cell therapy technology | |
Industry 2 | big data analysis | |
Person | Disley, Darrin M. (Mogrify 201902– CEO of Cell Mogrify Ltd before 11 years at Horizon Discovery) | |
Person 2 | Schmitt, Karin (Mogrify 201910 CBO) | |
Region | Cambridge, Cambridgeshire | |
Country | United Kingdom (GB) | |
Street | Bio-Innovation Centre Cambridge Science Park | |
City | CB4 0FW Cambridge | |
Tel | +44-1223-734154 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2019-10-14) |
* Document for »About Section«: Mogrify Ltd.. (7/5/22). "Press Release: Mogrify and Astellas Announce Collaboration to Conduct Research on in vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss". Cambridge & Tokyo. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Mogrify (Group)
- [1] Mogrify Ltd.. (10/2/23). "Press Release: Mogrify Extends Series A Financing to $46 Million USD". Cambridge....
- [2] Mogrify Ltd.. (7/5/22). "Press Release: Mogrify and Astellas Announce Collaboration to Conduct Research on in vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss". Cambridge & Tokyo....
- [3] Mogrify Ltd.. (5/4/21). "Press Release: Mogrify Completes Series A financing Totaling $33 Million USD". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top